Table 4.
Summary of some relevant nanovaccine-delivery systems that are being evaluated in clinical trials
| Name/Company | Nanocarrier | Disease | Vaccination route | Clinical Phase | Ref. |
|---|---|---|---|---|---|
| SELA-070/Selecta Biosciences | Synthetic Vaccine Particles (SVP™) | Smoking cessation and relapse prevention | Parenteral (SC) | Phase I | [190, 191] |
| MAS-1/Nova Immunotherapeutics Limited | Nanoparticular emulsion-based adjuvant | Seasonal Influenza | Parenteral | Phase I | [192, 193] |
| FluGem®/Mucosis BV | Bacterium-like particles | Influenza | Mucosal (IN) | Phase I | [194, 195] |
| SynGem®/Mucosis BV | RSV | Mucosal (IN) | Phase I | [194, 196] | |
| VCL-HB01/Vical Inc | Vaxfectin® adjuvant: cationic lipid-based liposomes | HSV-2 | Parenteral (IM) | Phase II | [197, 198] |
| ASP0113/Vical Inc | Poloxamer CRL1005+ DNA | CMV in hematopoietic cell transplant patients | Parenteral (IM) | Phase III | [199, 200] |
| CMV | Phase II | [199, 201] | |||
| HBV003/Vaxine Pty Ltd | Advax: D-inulin MPs | Hepatitis B | Parenteral (IM) | Phase I/II | [202, 203] |
| FLU003/Vaxine Pty Ltd | H5N1 Avian Influenza | Parenteral (IM) | Phase I | [202, 204] | |
| R21 + Matrix M1/University of Oxford & Novavax | Antigen + Matrix M™: saponin-based particles (saponins, synthetic Chol and phospholipids) | Malaria | Parenteral (IM) | Phase I/II | [205, 206] |
| RSV F Vaccine/Novavax | RSV F Vaccine: recombinant F-proteins from RSV that self-assemble to form NPs | RSV | Parenteral (IM) | Phase III | [207, 208] |
| RSV F Vaccine + Matrix M/Novavax | RSV F Vaccine + Matrix M™ | RSV | Parenteral (IM) | Phase II and III | [205, 208, 209] |
| LV305/Immune Design | LVR305: Antigen-specific ZVex® vector (hybrid, reengineered virus designed to carry genetic information of a tumor antigen) | Non-small cell lung cancer, Melanoma and Sarcoma | Parenteral (ID) | Phase I | [210 – 212] |
| CMB305/Immune Design | LV305 + G305(GLA adjuvant system) | Sarcoma, Melanoma, Non-small cell lung cancer and Ovarian cancer | Parenteral (ID and IM) | Phase I | [210, 211, 213] |
| JVRS-100/Juvaris Biotherapeutics Inc | JVRS-100: cationic lipids/non-coding DNA plasmid complexes | Leukaemia | Parenteral (IV) | Phase I | [214, 215] |
| 1790GAHB/GlaxoSmithKline | GMMA: outer membrane particles from bacteria | Dysentery | Parenteral (IM) | Phase I | [216, 217] |
| CTH522-CAF01/Statens Serum Institut | CAF01: cationic adjuvant system composed of DDA and TDB | Chlamydia trachomatis | Parenteral (IM) | Phase I | [126, 218] |
Chol: cholesterol; CMV: cytomegalovirus; DDA: dimethyldioctadecylammonium; GLA: glucopyranosyl lipid A; GMMA: generalized modules of membrane antigen; HSV-2: Herpes Simplex Virus - 2; ID: intradermal; IM: intramuscular; IN: intranasal; MP: microparticle; NP: nanoparticle; RSV: Respiratory Syncital Virus; SC: subcutaneous; TDB: trehalose 6,6′-dibehenate